AIMAIM ImmunoTech Inc.

NYSE aimimmuno.com


$ 0.43 $ 0.02 (5.34 %)    

Friday, 26-Apr-2024 15:59:26 EDT
QQQ $ 431.01 $ 6.55 (1.54 %)
DIA $ 382.27 $ 1.39 (0.36 %)
SPY $ 508.26 $ 4.77 (0.95 %)
TLT $ 88.26 $ 0.46 (0.52 %)
GLD $ 216.60 $ 0.70 (0.32 %)
$ 0.4282
$ 0.42
$ 0.00 x 0
$ 0.00 x 0
$ 0.42 - $ 0.43
$ 0.32 - $ 0.75
85,255
na
20.8M
$ -0.16
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 03-30-2024 12-31-2023 10-K
2 11-14-2023 09-30-2023 10-Q
3 08-14-2023 06-30-2023 10-Q
4 05-15-2023 03-31-2023 10-Q
5 03-31-2023 12-31-2022 10-K
6 11-14-2022 09-30-2022 10-Q
7 08-15-2022 06-30-2022 10-Q
8 05-13-2022 03-31-2022 10-Q
9 03-31-2022 12-31-2021 10-K
10 11-15-2021 09-30-2021 10-Q
11 08-16-2021 06-30-2021 10-Q
12 05-17-2021 03-31-2021 10-Q
13 03-31-2021 12-31-2020 10-K
14 11-12-2020 09-30-2020 10-Q
15 08-14-2020 06-30-2020 10-Q
16 05-14-2020 03-31-2020 10-Q
17 03-30-2020 12-31-2019 10-K
18 11-14-2019 09-30-2019 10-Q
19 08-14-2019 06-30-2019 10-Q
20 05-15-2019 03-31-2019 10-Q
21 04-01-2019 12-31-2018 10-K
22 11-14-2018 09-30-2018 10-Q
23 08-14-2018 06-30-2018 10-Q
24 05-15-2018 03-31-2018 10-Q
25 03-30-2018 12-31-2017 10-K
26 11-14-2017 09-30-2017 10-Q
27 08-14-2017 06-30-2017 10-Q
28 05-15-2017 03-31-2017 10-Q
29 03-31-2017 12-31-2016 10-K
30 11-14-2016 09-30-2016 10-Q
31 08-15-2016 06-30-2016 10-Q
32 05-16-2016 03-31-2016 10-Q
33 03-29-2016 12-31-2015 10-K
34 11-16-2015 09-30-2015 10-Q
35 08-12-2015 06-30-2015 10-Q
36 05-12-2015 03-31-2015 10-Q
37 03-19-2015 12-31-2014 10-K
38 11-07-2014 09-30-2014 10-Q
39 08-08-2014 06-30-2014 10-Q
40 05-09-2014 03-31-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 aim-immunotech-q4-eps-026-misses-015-estimate-sales-6500k-beat-4000k-estimate

AIM ImmunoTech (AMEX:AIM) reported quarterly losses of $(0.26) per share which missed the analyst consensus estimate of $(0.15)...

 earnings-scheduled-for-april-2-2024

Companies Reporting Before The Bell • Ocugen (NASDAQ:OCGN) is estimated to report earnings for its fourth quarter.

 earnings-scheduled-for-march-26-2024

Companies Reporting Before The Bell • bluebird bio (NASDAQ:BLUE) is likely to report quarterly loss at $0.66 per share on reve...

 aim-immunotech-and-3-other-stocks-under-3-insiders-are-buying

The Dow Jones index closed lower by over 300 points on Friday. When insiders purchase or sell shares, it indicates their confid...

 aim-immunotech-launches-ceo-corner-platform

CEO Corner segments to provide added perspective to press releases, corporate developments and pipeline progress Provides inter...

Core News & Articles

The DURIPANC Study is an investigator-initiated, exploratory, open-label, single-center study with the full name "Combining...

 aim-immunotech-reports-topline-results-from-phase-2-study-evaluating-ampligen-for-treatment-of-post-covid-conditions

Efficacy results offer preliminary evidence that Ampligen may reduce fatigue in subjects with Post-COVID conditions Safety resu...

Core News & Articles

AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced that the first subject has been enrolle...

Core News & Articles

First enrollment and first subject dosing expected soon at Erasmus Medical Center in Rotterdam, Netherlands 

 kellner-group-issued-statement-in-connection-with-their-efforts-to-bring-accountability-to-the-aim-immunotech-board-of-directors

On December 28, 2023, the Delaware Court of Chancery ruled in Mr. Kellner's favor that four separate advance notice bylaw p...

 aim-immunotech-and-3-other-stocks-under-1-insiders-are-buying

The Dow Jones closed lower by over 50 points on Monday. When insiders purchase or sell shares, it indicates their confidence or...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION